This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Oculusgen (Ologen) Glaucoma MMC Control in Estonia

This study has been completed.
Information provided by (Responsible Party):
Pro Top & Mediking Company Limited Identifier:
First received: September 4, 2007
Last updated: June 26, 2017
Last verified: June 2017

To compare the safety and effectiveness between ologen collagen matrix and mitomycin-C (MMC) in glaucoma surgery.

The ologen collagen matrix implantation procedure is same as traditional trabeculectomy except implant the ologen collagen matrix on the top of sclera flap after one loose stich the sclera flap. The MMC application is as the standard.

Condition Intervention Phase
Open Angle Glaucoma Angle Closure Glaucoma Uveitis Glaucoma Young Age Glaucoma Neovascular Glaucoma High Risk Patient Device: ologen (oculusgen) collagen matrix Drug: MMC in Trabeculectomy Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comprative Study of the Safety and Effectiveness Between Oculusgen (Ologen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery

Resource links provided by NLM:

Further study details as provided by Pro Top & Mediking Company Limited:

Primary Outcome Measures:
  • IOP <21mmHg without anti glaucoma medication [ Time Frame: 180 days ]

Secondary Outcome Measures:
  • IOP<21mmHg or IOP drops more than 30% with anti glaucoma medication [ Time Frame: 180-day ]

Estimated Enrollment: 20
Study Start Date: July 2007
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ologen in Trabeculectomy
Ologen in Trabeculectomy
Device: ologen (oculusgen) collagen matrix
Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
Other Names:
  • ologen collagen matrix
  • oculusgen collagen matrix
Active Comparator: MMC in Trabeculectomy
MMC in Trabeculectomy
Drug: MMC in Trabeculectomy
MMC in Trabeculectomy

Detailed Description:

Ologen collagen matrix is implanted on the top of sclera flap after the loose stich sclera flap is done for the filtering surgery. The concept of ologen collagen matrix is to creat the subconjunctiva bleb and modulate the wound healing for the surgery. By implanting ologen collagen matrix in the place, subconjuctival and trabdoor scars might be prevented. This is because the ologen collagen matrix is a 3-D scaffold porous structure that can guide fibroblast to grow randomly, instead of linear alignment. This can reduce the scar formation.

Doctors apply MMC for the glaucoma surgery is also trying to inhibite the scar formation. But MMC has been long time used and glaucoma specialists have not found anything to replace it.

Ologen collagen matrix concept is not INHIBITION, it is guiding and creating a physiological tissue. The successful of ologen collagen matrix may be on par with MMC but the safety and side effects will be much less.


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Max anti glaucoma medication failed,

Exclusion Criteria:

  • Age less than 18, woman in pregnant, hemodialysis patient
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00524758

Tartu University Clinics
Tartu, Estonia
Sponsors and Collaborators
Pro Top & Mediking Company Limited
Principal Investigator: Kuldar Kaljurand, MD University of Tartu
  More Information

Responsible Party: Pro Top & Mediking Company Limited Identifier: NCT00524758     History of Changes
Other Study ID Numbers: oculusgen 2006-02-20
Study First Received: September 4, 2007
Last Updated: June 26, 2017

Keywords provided by Pro Top & Mediking Company Limited:
collagen matrix
filtering surgery
Aeon Astron

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Glaucoma, Angle-Closure
Glaucoma, Neovascular
Ocular Hypertension
Eye Diseases
Uveal Diseases
Antibiotics, Antineoplastic
Antineoplastic Agents
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors processed this record on September 21, 2017